Study of SPG601 in Adult Men With Fragile X Syndrome
Status:
COMPLETED
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This Phase 2 study described herein will evaluate the safety, efficacy, tolerability, pharmacokinetics and pharmacodynamics of SPG601 in adult men with Fragile X syndrome.